EP3442991A4 - PIN BINDING PEPTIDES AND METHODS OF USE - Google Patents
PIN BINDING PEPTIDES AND METHODS OF USE Download PDFInfo
- Publication number
- EP3442991A4 EP3442991A4 EP17783273.0A EP17783273A EP3442991A4 EP 3442991 A4 EP3442991 A4 EP 3442991A4 EP 17783273 A EP17783273 A EP 17783273A EP 3442991 A4 EP3442991 A4 EP 3442991A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- binding peptides
- pin binding
- pin
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323115P | 2016-04-15 | 2016-04-15 | |
| PCT/US2017/027697 WO2017181061A1 (en) | 2016-04-15 | 2017-04-14 | Ras binding peptides and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3442991A1 EP3442991A1 (en) | 2019-02-20 |
| EP3442991A4 true EP3442991A4 (en) | 2019-11-20 |
Family
ID=60042269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17783273.0A Withdrawn EP3442991A4 (en) | 2016-04-15 | 2017-04-14 | PIN BINDING PEPTIDES AND METHODS OF USE |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US10954287B2 (en) |
| EP (1) | EP3442991A4 (en) |
| WO (1) | WO2017181061A1 (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852183B (en) | 2011-12-28 | 2024-08-11 | 日商中外製藥股份有限公司 | Cyclization method of peptide compounds |
| US10815489B2 (en) | 2015-03-13 | 2020-10-27 | Chugai Seiyaku Kabushiki Kaisha | Modified aminoacyl-tRNA synthetase and use thereof |
| WO2018085208A1 (en) | 2016-11-02 | 2018-05-11 | The Research Foundation For The State University Of New York | Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction |
| US12391971B2 (en) | 2017-01-31 | 2025-08-19 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptides in cell-free translation system |
| EP3636656A4 (en) | 2017-06-09 | 2021-04-14 | Chugai Seiyaku Kabushiki Kaisha | PROCESS FOR SYNTHESIS OF A PEPTIDE CONTAINING AN N-SUBSTITUTED AMINO ACID |
| CN111479819B (en) | 2017-12-15 | 2024-06-14 | 中外制药株式会社 | Method for preparing peptide and method for treating base |
| JP7386852B2 (en) * | 2018-05-15 | 2023-11-27 | インテルク ペプチド セラピューティクス リミテッド | Peptide activator |
| SG11202012653XA (en) | 2018-06-19 | 2021-01-28 | Biontech Us Inc | Neoantigens and uses thereof |
| EP3810129B1 (en) | 2018-06-21 | 2023-08-16 | Merck Sharp & Dohme LLC | Pcsk9 antagonist bicyclo-compounds |
| KR20250161677A (en) | 2018-06-21 | 2025-11-17 | 머크 샤프 앤드 돔 엘엘씨 | Pcsk9 antagonist compounds |
| WO2019246405A1 (en) | 2018-06-21 | 2019-12-26 | Merck Sharp & Dohme Corp. | Cyclic polypeptides for pcsk9 inhibition |
| ES3015132T3 (en) | 2018-06-21 | 2025-04-29 | Ucb Holdings Inc | Cyclic polypeptides for pcsk9 inhibition |
| EP3810178A4 (en) | 2018-06-21 | 2022-05-04 | Merck Sharp & Dohme Corp. | CYCLIC POLYPEPTIDES FOR INHIBITION OF PCSK9 |
| US11814444B2 (en) | 2018-06-21 | 2023-11-14 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for PCSK9 inhibition |
| WO2020027225A1 (en) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | Heterocyclic compound |
| US12312297B2 (en) | 2018-11-07 | 2025-05-27 | Chugai Seiyaku Kabushiki Kaisha | O-substituted serine derivative production method |
| CN119143631A (en) | 2018-11-30 | 2024-12-17 | 中外制药株式会社 | Deprotection method for peptide compound or amide compound and resin removal method in solid phase reaction and method for producing peptide compound |
| KR102994657B1 (en) | 2019-03-15 | 2026-07-22 | 추가이 세이야쿠 가부시키가이샤 | Method for preparing aromatic amino acid derivatives |
| CA3142404A1 (en) | 2019-06-07 | 2020-12-10 | Emory University | Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto |
| WO2020257405A1 (en) * | 2019-06-18 | 2020-12-24 | Musc Foundation For Research Development | Compositions and methods targeting the nucleotide free state of ras to block oncogenic signaling and transformation |
| EP4021919A1 (en) | 2019-08-30 | 2022-07-06 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
| MX2022005359A (en) * | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Ras inhibitors. |
| EP4043478A4 (en) | 2019-11-07 | 2024-01-03 | Chugai Seiyaku Kabushiki Kaisha | Cyclic peptide compound having kras inhibiting action |
| WO2021090856A1 (en) | 2019-11-07 | 2021-05-14 | 中外製薬株式会社 | Method for producing peptide compound comprising highly sterically hindered amino acid |
| CN111393519B (en) * | 2019-11-21 | 2022-11-08 | 中国药科大学 | Novel stapled peptides as KRASG12C/SOS1 inhibitors and uses thereof |
| US12577259B2 (en) | 2019-12-20 | 2026-03-17 | Merck Sharp & Dohme Llc | PCSK9 antagonist compounds |
| WO2021142022A2 (en) * | 2020-01-06 | 2021-07-15 | Quanta Therapeutics, Inc. | Compositions and methods for identification of modulators of ras protein complexes |
| US20230242586A1 (en) * | 2020-04-23 | 2023-08-03 | The Regents Of The University Of California | Ras inhibitors and uses thereof |
| US11932705B2 (en) | 2020-12-18 | 2024-03-19 | Merck Sharp & Dohme Llc | Cyclic polypeptides for PCSK9 inhibition |
| WO2022234639A1 (en) * | 2021-05-07 | 2022-11-10 | 中外製薬株式会社 | Bonding molecule exhibiting selective bonding to variant ras (g12d) |
| KR20230169093A (en) | 2021-05-07 | 2023-12-15 | 추가이 세이야쿠 가부시키가이샤 | Preparation containing cyclic peptide compound and method for producing same |
| AR125796A1 (en) * | 2021-05-07 | 2023-08-16 | Chugai Pharmaceutical Co Ltd | CYCLIC COMPOUND THAT HAS A SELECTIVE INHIBITORY ACTION IN KRAS ON HRAS AND NRAS |
| AR125800A1 (en) | 2021-05-07 | 2023-08-16 | Chugai Pharmaceutical Co Ltd | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACIDS RESIDUES |
| BR112023022875A2 (en) | 2021-05-07 | 2024-01-23 | Chugai Pharmaceutical Co Ltd | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND |
| EP4448544A2 (en) * | 2021-12-17 | 2024-10-23 | 3B Pharmaceuticals GmbH | Carbonic anhydrase ix ligands |
| IL316253A (en) | 2022-05-06 | 2025-01-01 | Chugai Pharmaceutical Co Ltd | Cyclic compound having selective kras inhibitory effect on hras and nras |
| KR20240082196A (en) | 2022-11-09 | 2024-06-10 | 추가이 세이야쿠 가부시키가이샤 | Pharmaceutical composition comprising cyclic compound having selective inhibitory action on kras over hras and nras |
| WO2025148868A1 (en) * | 2024-01-08 | 2025-07-17 | 泰励生物科技（上海）有限公司 | Antibody-drug conjugate and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910478A (en) * | 1995-09-21 | 1999-06-08 | Innapharma, Inc. | Peptidomimetics inhibiting the oncogenic action of p21 ras |
| WO2012162628A2 (en) * | 2011-05-25 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lipopeptide inhibitors of ras oncoproteins |
| US20150239935A1 (en) * | 2011-03-04 | 2015-08-27 | New York University | Hydrogen bond surrogate macrocycles as modulators of ras |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| DE69233528T2 (en) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Process for the preparation of multivalent antigen-binding proteins |
| CA2257108A1 (en) * | 1996-06-07 | 1997-12-11 | Takeda Chemical Industries, Ltd. | Novel peptides and production and use thereof |
| US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
| JP3614866B2 (en) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | Artificial antibody polypeptide |
| IL140930A0 (en) | 1998-08-07 | 2002-02-10 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
| PL1888031T3 (en) | 2005-06-06 | 2013-04-30 | Camurus Ab | GLP-1 ANALOGUE PREPARATIONS |
| WO2009067191A2 (en) | 2007-11-16 | 2009-05-28 | The General Hospital Corporation | Methods and compositions for the treatment of hepatitis c virus (hcv) infection |
| EP2649099A4 (en) | 2010-12-07 | 2016-10-19 | Univ Yale | HYDROPHOBIC MARKING OF SMALL MOLECULES OF FUSION PROTEINS AND INDUCED DEGRADATION THEREOF |
| US9238676B2 (en) * | 2012-05-17 | 2016-01-19 | Ra Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
| US10017540B2 (en) | 2015-03-11 | 2018-07-10 | California Institute Of Technology | Cyclic peptide binder against oncogenic K-Ras |
-
2017
- 2017-04-14 EP EP17783273.0A patent/EP3442991A4/en not_active Withdrawn
- 2017-04-14 US US16/093,762 patent/US10954287B2/en not_active Expired - Fee Related
- 2017-04-14 WO PCT/US2017/027697 patent/WO2017181061A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910478A (en) * | 1995-09-21 | 1999-06-08 | Innapharma, Inc. | Peptidomimetics inhibiting the oncogenic action of p21 ras |
| US20150239935A1 (en) * | 2011-03-04 | 2015-08-27 | New York University | Hydrogen bond surrogate macrocycles as modulators of ras |
| WO2012162628A2 (en) * | 2011-05-25 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lipopeptide inhibitors of ras oncoproteins |
Non-Patent Citations (4)
| Title |
|---|
| PUNIT UPADHYAYA ET AL: "Inhibition of Ras Signaling by Blocking Ras-Effector Interactions with Cyclic Peptides", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 54, no. 26, 22 June 2015 (2015-06-22), DE, pages 7602 - 7606, XP055238762, ISSN: 1433-7851, DOI: 10.1002/anie.201502763 * |
| See also references of WO2017181061A1 * |
| THI B. TRINH ET AL: "Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides", ACS COMBINATORIAL SCIENCE, vol. 18, no. 1, 11 January 2016 (2016-01-11), US, pages 75 - 85, XP055431276, ISSN: 2156-8952, DOI: 10.1021/acscombsci.5b00164 * |
| WATKINS ANDREW M ET AL: "Structure-based inhibition of protein-protein interact", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 94, 16 September 2014 (2014-09-16), pages 480 - 488, XP029123808, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2014.09.047 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US10954287B2 (en) | 2021-03-23 |
| EP3442991A1 (en) | 2019-02-20 |
| WO2017181061A1 (en) | 2017-10-19 |
| US20190119358A1 (en) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43816A (en) | INDUCTIBLE BINDING PROTEINS AND METHODS OF USE | |
| MA47113A (en) | ANTI-NEUROPILINE ANTIGEN BINDING PROTEINS AND THEIR METHODS OF USE | |
| FR24C1033I2 (en) | PD-1 BINDING MOLECULES AND METHODS OF USE THEREOF | |
| EP3355920A4 (en) | PD-1 BINDING PROTEINS AND METHODS OF USE | |
| EP3436068A4 (en) | BINDING PROTEINS AND METHODS OF USE THEREOF | |
| IL271275A (en) | Preparations containing coronas and their uses | |
| EP3694529A4 (en) | TRISPECIFIC PROTEINS AND METHODS OF USE | |
| EP3678731A4 (en) | HAEMOSTATIC VALVES AND METHODS OF USE | |
| EP3802581A4 (en) | MULTISPECIFIC BINDING PROTEINS AND IMPROVEMENTS THEREOF | |
| EP3655432A4 (en) | BINDING PROTEIN 1 | |
| EP3426298A4 (en) | ILT7 BINDING MOLECULES AND METHODS OF USE | |
| EP3302562A4 (en) | LAG-3 BINDING MOLECULES AND METHODS OF USE THEREOF | |
| EP3634430A4 (en) | MULTIBIOTIC AGENTS AND METHODS OF USE THEREOF | |
| EP3500594A4 (en) | ANTIBODIES, BINDING FRAGMENTS, AND METHODS OF USE | |
| EP3429591A4 (en) | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE | |
| MA42925A (en) | ANTI-TIGIT ANTIBODIES AND METHODS OF USE | |
| EP3455263A4 (en) | CD40L-FC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | |
| EP3337517A4 (en) | ANTI-DLL3 ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE | |
| EP3390624A4 (en) | MODIFIED TARGETED MODIFICATION POLYPEPTIDES AND METHODS OF USE | |
| EP3484488A4 (en) | ANTI-BINDING MOLECULES AND METHOD FOR USE THEREOF | |
| EP3423438A4 (en) | PHYTOVIRUS MOTION PROTEINS AND METHODS OF USE THEREOF | |
| HUE060182T2 (en) | Somatostatin modulators and their use | |
| HUE052468T2 (en) | Arginase inhibitors and their therapeutic applications | |
| EP3436022A4 (en) | OXYSTEROLS AND THEIR METHODS OF USE | |
| EP3319944A4 (en) | MDM2-BASED PROTEASE MODULATORS AND METHODS OF USE THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20181015 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TRECO, DOUGLAS A. Inventor name: NIMS, NATHAN EZEKIEL Inventor name: SEYB, KATHLEEN Inventor name: VADYSIRISACK, DOUANGSONE D. Inventor name: TANG, GUO-QING Inventor name: MA, ZHONG Inventor name: TOBE, SYLVIA Inventor name: SUN, YILI Inventor name: JOSEPHSON, KRISTOPHER Inventor name: YE, PING |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SUN, YILI Inventor name: TOBE, SYLVIA Inventor name: TRECO, DOUGLAS A. Inventor name: SEYB, KATHLEEN Inventor name: MA, ZHONG Inventor name: TANG, GUO-QING Inventor name: VADYSIRISACK, DOUANGSONE D. Inventor name: JOSEPHSON, KRISTOPHER Inventor name: NIMS, NATHAN EZEKIEL Inventor name: YE, PING |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20191023 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/00 20060101ALI20191017BHEP Ipc: C07K 14/82 20060101ALI20191017BHEP Ipc: G01N 33/574 20060101ALI20191017BHEP Ipc: C07K 7/08 20060101AFI20191017BHEP Ipc: A61P 35/00 20060101ALI20191017BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20210414 |